Patents by Inventor Xiangqun Gao

Xiangqun Gao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Prevention and treatment of oxidative stress disorders by gluthathione and phase II detoxification enzymes
    Patent number: 8709406
    Abstract: The present invention generally relates to the field of treating oxidative stress disorders by administering a pharmaceutically effective amount of a compound that elevates the intracellular levels of glutathone or intracelluar levels of at least one Phase II detoxification enzyme in animal tissue. The present invention also relates to the field of protecting a subject from oxidative stress disorders by administering a pharmaceutically effective amount of a compound that elevates the intracellular levels of glutathone or intracelluar levels of at least one Phase II detoxification enzyme in the subject. The present invention also relates to a pharmaceutical composition useful for the treatment of oxidative stress disorders.
    Type: Grant
    Filed: November 6, 2012
    Date of Patent: April 29, 2014
    Assignee: Brassica Foundation for Chemoprotection Research, Inc.
    Inventors: Xiangqun Gao, Albena T. Dinkova-Kostova, Paul Talalay
  • Prevention and treatment of oxidative stress disorders by glutathione and phase II detoxification enzymes
    Patent number: 8303949
    Abstract: The present invention generally relates to the field of treating oxidative stress disorders by administering a pharmaceutically effective amount of a compound that elevates the intracellular levels of glutathone or intracelluar levels of at least one Phase II detoxification enzyme in animal tissue. The present invention also relates to the field of protecting a subject from oxidative stress disorders by administering a pharmaceutically effective amount of a compound that elevates the intracellular levels of glutathone or intracelluar levels of at least one Phase II detoxification enzyme in the subject. The present invention also relates to a pharmaceutical composition useful for the treatment of oxidative stress disorders.
    Type: Grant
    Filed: July 25, 2008
    Date of Patent: November 6, 2012
    Assignee: Brassica Foundation for Chemoprotection Research, Inc.
    Inventors: Xiangqun Gao, Albena T. Dinkova-Kostova, Paul Talalay
  • PREVENTION AND TREATMENT OF OXIDATIVE STRESS DISORDERS BY GLUTATHIONE AND PHASE II DETOXIFICATION ENZYMES
    Publication number: 20090017002
    Abstract: The present invention generally relates to the field of treating oxidative stress disorders by administering a pharmaceutically effective amount of a compound that elevates the intracellular levels of glutathone or intracelluar levels of at least one Phase II detoxification enzyme in animal tissue. The present invention also relates to the field of protecting a subject from oxidative stress disorders by administering a pharmaceutically effective amount of a compound that elevates the intracellular levels of glutathone or intracelluar levels of at least one Phase II detoxification enzyme in the subject. The present invention also relates to a pharmaceutical composition useful for the treatment of oxidative stress disorders.
    Type: Application
    Filed: July 25, 2008
    Publication date: January 15, 2009
    Inventors: Xiangqun Gao, Albena T. Dinkova-Kostova, Paul Talalay
  • Prevention and treatment of oxidative stress disorders by glutathione and phase II detoxification enzymes
    Patent number: 7407986
    Abstract: The present invention generally relates to the field of treating oxidative stress disorders by administering a pharmaceutically effective amount of a compound that elevates the intracellular levels of glutathone or intracellular levels of at least one Phase II detoxification enzyme in animal tissue. The present invention also relates to the field of protecting a subject from oxidative stress disorders by administering a pharmaceutically effective amount of a compound that elevates the intracellular levels of glutathone or intracellular levels of at least one Phase II detoxification enzyme in the subject. The present invention also relates to a pharmaceutical composition useful for the treatment of oxidative stress disorders.
    Type: Grant
    Filed: December 18, 2002
    Date of Patent: August 5, 2008
    Assignee: Brassica Foundation for Chemoprotection Research, Inc.
    Inventors: Xiangqun Gao, Albena T. Dinkova-Kostova, Paul Talalay
  • Prevention and treatment of oxidative stress disorders by glutathione and phase II detoxification enzymes
    Publication number: 20050063965
    Abstract: The present invention generally relates to the field of treating oxidative stress disorders by administering a pharmaceutically effective amount of a compound that elevates the intracellular levels of glutathone or intracellular levels of at least one Phase II detoxification enzyme in animal tissue. The present invention also relates to the field of protecting a subject from oxidative stress disorders by administering a pharmaceutically effective amount of a compound that elevates the intracellular levels of glutathone or intracellular levels of at least one Phase II detoxification enzyme in the subject. The present invention also relates to a pharmaceutical composition useful for the treatment of oxidative stress disorders.
    Type: Application
    Filed: December 18, 2002
    Publication date: March 24, 2005
    Applicant: Brassica Foundation for Chemoprotection Research Inc
    Inventors: Xiangqun Gao, Albena Dinkova-Kostova, Paul Talalay